tetano
Editor, Senior Moderator
Vaccine. 2014 Nov 17. pii: S0264-410X(14)01530-8. doi: 10.1016/j.vaccine.2014.11.006. [Epub ahead of print]
Increasing uptake of live attenuated influenza vaccine among children in the United States, 2008-2014.
Rodgers L1, Pabst LJ2, Chaves SS3.
Author information
Abstract
The Advisory Committee on Immunization Practices (ACIP) recommends annual influenza vaccination for all persons in the United States aged ≥6 months. On June 25, 2014, ACIP preferentially recommended live attenuated influenza vaccine (LAIV) for healthy children aged 2-8 years [1]. Little is known about national LAIV uptake. To determine uptake of LAIV relative to inactivated influenza vaccine, we analyzed vaccination records from six immunization information system sentinel sites (approximately 10% of US population). LAIV usage increased over time in all sites. Among children 2-8 years of age vaccinated for influenza, exclusive LAIV usage in the collective sentinel site area increased from 20.1% (2008-09 season) to 38.0% (2013-14). During 2013-14, at least half of vaccinated children received LAIV in Minnesota (50.0%) and North Dakota (55.5%). Increasing LAIV usage suggests formulation acceptability, and this preexisting trend offers a favorable context for implementation of ACIP's preferential recommendation.
Published by Elsevier Ltd.
KEYWORDS:
Child, Preschool; Immunization information systems; Influenza vaccines; Influenza, Human; Registries; Vaccination; Vaccine coverage
PMID:
25448098
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25448098
Increasing uptake of live attenuated influenza vaccine among children in the United States, 2008-2014.
Rodgers L1, Pabst LJ2, Chaves SS3.
Author information
Abstract
The Advisory Committee on Immunization Practices (ACIP) recommends annual influenza vaccination for all persons in the United States aged ≥6 months. On June 25, 2014, ACIP preferentially recommended live attenuated influenza vaccine (LAIV) for healthy children aged 2-8 years [1]. Little is known about national LAIV uptake. To determine uptake of LAIV relative to inactivated influenza vaccine, we analyzed vaccination records from six immunization information system sentinel sites (approximately 10% of US population). LAIV usage increased over time in all sites. Among children 2-8 years of age vaccinated for influenza, exclusive LAIV usage in the collective sentinel site area increased from 20.1% (2008-09 season) to 38.0% (2013-14). During 2013-14, at least half of vaccinated children received LAIV in Minnesota (50.0%) and North Dakota (55.5%). Increasing LAIV usage suggests formulation acceptability, and this preexisting trend offers a favorable context for implementation of ACIP's preferential recommendation.
Published by Elsevier Ltd.
KEYWORDS:
Child, Preschool; Immunization information systems; Influenza vaccines; Influenza, Human; Registries; Vaccination; Vaccine coverage
PMID:
25448098
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25448098